Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

scientific article published in March 2005

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/J.1398-9995.2004.00772.X
P8608Fatcat IDrelease_4opf5kmwlfb65jipvztxjetn6u
P698PubMed publication ID15679715
P5875ResearchGate publication ID8051812

P50authorGiorgio Walter CanonicaQ56380976
Marc HumbertQ33113039
Richard BeasleyQ37838402
P2093author name stringBousquet J
Beeh KM
Fox H
Ayres J
Hébert J
Ramos S
Blogg M
Hedgecock S
Surrey K
Slavin R
P2860cites workRisk factors for near-fatal asthma. A case-control study in hospitalized patients with asthma.Q50883385
A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonistsQ34727247
P433issue3
P921main subjectasthmaQ35869
P304page(s)309-316
P577publication date2005-03-01
P1433published inAllergyQ2699825
P1476titleBenefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
P478volume60